Inovio cytomegalovirus DNA vaccine

The Inovio cytomegalovirus (CMV) DNA vaccine is a preclinical candidate developed by Inovio Pharmaceuticals in collaboration with the University of Pennsylvania. Utilizing Inovio's proprietary SynCon® technology, the vaccine consists of synthetic DNA plasmids encoding multiple CMV antigens, including the gB, gH, and gL glycoproteins. To enhance the immune response, the vaccine is formulated with an optimized Interleukin-12 (IL-12) cytokine gene adjuvant. The vaccine is designed for intradermal or intramuscular administration followed by electroporation using the CELLECTRA® device, which facilitates cellular uptake of the DNA. Preclinical studies demonstrated the vaccine's ability to induce robust CD8+ T-cell and antibody responses. Despite these results, the candidate was never advanced into clinical trials and is no longer listed in Inovio's active development pipeline.

Other names

CMV DNA vaccineSynCon CMV vaccinecytomegalovirus DNA vaccine